Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]
港股异动 | 宜明昂科-B(01541)涨超5% Treg细胞疗法备受关注 目前公司正积极推进泰泽苏拜单抗临床开发